Crispr Therapeutics AG vs TORM plc — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while TORM plc trades at $28.3 (market cap $2.93B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and TORM plc pays a 9.77% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TRMD | |
|---|---|---|
Market Cap | $5.23B | $2.93B |
Sector | Health | Technology |
52-Week High | $76.78 | $34.87 |
52-Week Low | $44.34 | $18.77 |
Enterprise Value | $3.65B | $3.82B |
Dividend Yield | — | 9.77% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →